Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rosuvastatin.

Christopher I Carswell1, Greg L Plosker, Blair Jarvis

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|September 25, 2002
PubMed
Summary

Rosuvastatin effectively lowers LDL cholesterol in patients with hypercholesterolaemia, outperforming other statins. This HMG-CoA reductase inhibitor demonstrates superior efficacy and tolerability in diverse dyslipidaemia profiles.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis.

CNS drugs·2020
Same author

Asenapine: A Review in Schizophrenia.

CNS drugs·2016
Same author

AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus.

Drugs·2015
Same author

Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.

Annals of internal medicine·2015
Same author

13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.

Drugs·2015
Same author

Acamprosate: A Review of Its Use in Alcohol Dependence.

Drugs·2015

Area of Science:

  • Cardiovascular Pharmacology
  • Lipid Metabolism Disorders

Background:

  • Dyslipidaemia poses a significant cardiovascular risk.
  • Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are key in managing lipid profiles.
  • Rosuvastatin is an HMG-CoA reductase inhibitor with a favorable drug interaction profile.

Purpose of the Study:

  • To evaluate the efficacy of rosuvastatin in improving lipid profiles.
  • To compare rosuvastatin's effectiveness against other statins like atorvastatin, simvastatin, and pravastatin.
  • To assess rosuvastatin's achievement of National Cholesterol Education Program (NCEP) target low-density lipoprotein (LDL)-cholesterol levels.

Main Methods:

  • Comparative clinical trials of 6 to 52 weeks duration.
  • Dose-titration studies comparing rosuvastatin with atorvastatin.
  • 1-year trials comparing rosuvastatin with pravastatin and simvastatin.

Main Results:

  • Rosuvastatin demonstrated superiority over atorvastatin, simvastatin, and pravastatin in improving lipid profiles.
  • Higher percentages of patients achieved NCEP target LDL-cholesterol levels with rosuvastatin compared to other statins, especially in high-risk groups.
  • Rosuvastatin improved lipid profiles in patients with familial hypercholesterolaemia, hypertriglyceridaemia, and mixed dyslipidaemias.

Conclusions:

  • Rosuvastatin is a highly effective HMG-CoA reductase inhibitor for managing hypercholesterolaemia and other dyslipidaemias.
  • Rosuvastatin offers superior efficacy in achieving LDL-cholesterol targets compared to atorvastatin, simvastatin, and pravastatin.
  • Rosuvastatin is well-tolerated in clinical trials up to one year in duration.

Related Experiment Videos